It is unclear whether SCLC-N truly represents a subtype of SCLC with distinct outcomes and therapeutic sensitivities (Gay et al., 2021), or rather a snapshot from a continuum in tumor evolution driven (principally) by MYC toward an aggressive, recalcitrant disease (Choudhuri et al., 2023; Pongor et al., 2023). The gene discussed is MYC; the disease is neoplasm.